奈达铂和顺铂同步放化疗治疗晚期宫颈癌的临床疗效比较

目的：比较奈达铂和顺铂同步放化疗治疗晚期宫颈癌的临床疗效及安全性。方法选择2011年1月～2013年3月我院收治的70例晚期宫颈癌患者，并将其随机分为观察组（奈达铂同步放化疗）和对照组（顺铂同步放化疗），每组35例。化疗4周后，观察和比较两组的客观有效率、疾病控制率、CD3＋、CD4＋、NK细胞的百分率及不良反应的发生情况。结果化疗前，两组患者免疫功能指标的差异无统计学意义（P〉0.05）；化疗后，观察组的客观有效率、疾病控制率以及CD3＋、CD4＋、NK细胞的百分率均显著高于对照组，不良反应的发生率显著低于对照组（P〈0.05）。结论奈达铂同步放化疗较顺铂同步放化疗治疗晚期宫颈癌更加有效，且安全性更好，具有更高的临床应用价值。

Comparison of the Clinical Efficacy between Nedaplatin and Cisplatin Concurrent Chemoradiotherapy in the Treatment of Advanced Cervical Carcinoma

Objective To compare the clinical efficacy between nedaplatin and cisplatin concurrent chemoradiotherapy in the treatment of advanced cervical carcinoma. Methods A total of 70 patients with advanced cervical cancer admitted in our hospital between January 2011 and March 2013 were enrolled in this study, and were randomly divided into observation group and control group, 35 cases in each group. Patients in the observation group were given nedaplatin concurrent chemo-radiotherapy, and those in the control group were given cisplatin concurrent chemoradiotherapy. After 4 weeks of chemo-therapy, the objective response rate, disease control rate, cellular immunological function and incidence of adverse reactions were observed and compared between the two groups. Results Before chemotherapy, the difference of immune function in-dex had no statistical significance （P〉0.05）. After chemotherapy, the objective response rate, disease control rate, and per-centages of CD3＋, CD4＋, NK cells of the observation group were significantly higher than those of the control group （P〈0.05）. In addition, the adverse reactions incidences of the observation group were lower than those of the control group （P〈0.05）. Conclusion The nedaplatin concurrent chemoradiotherapy had better clinical efficacy than of cisplatin concurrent chemo-radiotherapy in the treatment of advanced cervical carcinoma. It had better safety and higher clinical significance.